Back to search
Recurrent Uterine Sarcoma
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Recurrent Uterine Sarcoma trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Recurrent Uterine Sarcoma trials you may qualify forThis phase I/II trial evaluates the highest safe dose, side effects, and possible benefits of tegavivint in treating patients with solid tumors that has come ba…
To find the highest tolerable dose of IACS-6274 that can be given alone, in combination with bevacizumab and paclitaxel, or in combination with capivasertib to…
This study is being done to collect tissue samples to test how accurately a tumor response platform, Elephas, can predict clinical response across multiple type…
CoRDS, or the Coordination of Rare Diseases at Sanford, is based at Sanford Research in Sioux Falls, South Dakota. It provides researchers with a centralized, i…
This phase II trial studies the effects of the combination of olaparib and durvalumab, cediranib and durvalumab, olaparib and capivasertib, and cediranib alone…
This phase III trial studies how well the combination of pembrolizumab, paclitaxel and carboplatin works compared with paclitaxel and carboplatin alone in treat…